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30-day survival in patients with cardiogenic shock: Impella 2.5 versus
Impella 4.0
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BACKGROUND The Impella (Abiomed, Inc.) is a percutaneous left
ventricular assist device. It can be used in patients presenting with
acute myocardial infarction (AMI) complicated by cardiogenic shock
(CS) or in the elective setting for patients undergoing high-risk
percutaneous coronary intervention (PCI). Recently, the more
powerful Impella 4.0 (generating output up to 4L/min) was intro-
duced. In this retrospective study, we investigated 30-day outcome in
patients supported by Impella 2.5 or 4.0 in the acute setting of
cardiogenic shock.
METHODS From January 2009 till January 2015, 50 patients were
supported with the Impella-device in the Catharina Hospital Eind-
hoven, the Netherlands (a high-volume PCI centre). The Impella 2.5
was implanted from 2009 till 2013 and from 2013 the Impella 4.0 was
implanted exclusively. Study end point was 30-day survival.
RESULTS Patient characteristics were similar between the patient
groups treated by Impella 4.0 and Impella 2.5, respectively (table). Of
all 50 patients, 24 presented with AMI complicated by CS, 6 presented
with CS from other cause and 20 underwent high-risk elective PCI. In
the AMI plus CS-group, 13 patients were treated with Impella 4.0 and
11 patients were treated with Impella 2.5. All these patients were
treated by PCI and after 30 days, survival in the AMI plus CS Impella
4.0-group was signiﬁcantly higher compared to the AMI plus CS
Impella 2.5-group (46% versus 9%, P¼0.02) (ﬁgure). In patients
undergoing high-risk elective PCI, there was no difference in 30-day
survival between Impella 4.0 and Impella 2.5 (63% versus 61%,
P¼0.87).
Table. Baseline characteristicsImpella 4.0 acute + PCI (13) Impella 2.5 acute + PCI (11)Age (yrs) 5712 669
Male 9 (69%) 7 (64%)Diabetes 3 (23%) 3 (27%)Hypertension 6 (46%) 5 (45%)Hypercholesterolemia 2 (15%) 3 (27%)BMI (kg/cm2) 254 273
Previous MI 2 (15%) 2 (18%)Previous PCI 0 (0%) 1 (9%)Previous CABG 0 (0%) 0 (0%)Resuscitation 6 (46%) 7 (64%)Cardiogenic shock 13 (100%) 11 (100%)PCI 13 (100%) 11 (100%)LVEF < 30% 10 (77%) 9 (82%)MI ¼Myocardial infarction; PCI ¼ Percutaneous coronary intervention; CABG ¼ Coronary artery bypass graft;
LVEF ¼ Left ventricular ejection fractionCONCLUSIONS In this retrospective analysis, Impella 4.0 improved
survival signiﬁcantly in patients with AMI complicated by CS under-
going PCI compared to Impella 2.5. These novel ﬁndings support the
concept of the Impella-device. Randomized trials with the Impella 4.0
are warranted.
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BACKGROUND The Impella Circulatory Support System has been
developed to unload the left ventricle in patients with severely
reduced systolic function and to maintain basic circulation patients
with cardiogenic shock due to left-ventricular failure. We enrolled all
patients undergoing implantation of an Impella-pump in our depart-
ment into a registry to further analyze patient characteristics and
predictors of outcome.
METHODS Since July 2011 all patients, who received an Impella
microaxial pump were enrolled in our registry. Data on baseline
characteristics and in-hospital treatment including cardiovascular risk
factors, details on coronary angiography, hemodynamic parameters,
and laboratory parameters were documented in detail. Furthermore,
data on the outcome of those patients including follow-up until 12
months after implantation were recorded. In total, until June 2015, 175
patients underwent implantation of an Impella pump at our center.
Complete data including follow-up until 12 months are available in
100 patients.
RESULTS Cardiogenic shock was the indication for implantation in
85% of the cases, in the other patients the purpose for the implanta-
tion were high-risk percutaneous coronary interventions. In shock
patients mean age was 62 years (19-83 years). 74% of the patients were
male. Coronary heart disease was excluded by coronary angiography
in 21%. Median device time was 5 days (interquartile range (IQR) 1-7
days). In-hospital mortality was 8.3% in patients with isolated left-
ventricular dysfunction. Relevant contributors to worsened prognosis
were concomitant right-ventricular failure, necessity of additive
ECMO, new-onset dialysis, and pre-procedural cardiopulmonary
resuscitation. Higher body mass index (28.3 vs 25.9; p<0.01), right
heart failure (42% vs. 11%, p<0.05) and persistently elevated central
venous pressure after 6 hours (15 mmHg vs. 11 mmHg, p<0.05) were
more common in non-survivors. Neurological outcome was CPC class
1&2 in 91% of survivors. Average lactate levels were 6.7 mmol/L
(survivors) and 7.6 mmol/L (non-survivors; p¼0.652) during admis-
sion, 3.2 mmol/L (survivors) and 5.9 mmol/L (non-survivors; p¼0.028)
1h after Impella implantation, and 2.2 mmol/L (survivors) and 5.9
mmol/L (non-survivors; p¼0.008) 4h after Impella implantation.
